Subject: (Copy) NIH GUIDE - V20(41) 11/01/91 - P1/2
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Mon, 04 Nov 91 14:23 EST

Hi Paul,
   This is one of nine coming to you for posting to the NIH
Listserver.  Please post this one as:
    NIHGUIDE.911101
                   thanks
                          Dottie
 ---------------------------- Text of forwarded message -----------------------
 
$$XID NIHGUIDE 19911101 V20N41 P1O2 ************************************
X-comment: RFAS described: AG-91-15, ES-92-01, HD-92-02, NR-92-01, AI-91-13,
                           DK-92-07, DK-92-08
 
NIH GUIDE - Vol. 20, No. 41, November 1, 1991
 
$$INDEX BEGIN *******************************************************
 
                                      NOTICES
 
$$INDEX N1 **********************************************************
 
CARDIOVASCULAR IMAGING WORKSHOP
National Heart, Lung, and Blood Institute
INDEX:  HEART, LUNG, BLOOD
 
$$INDEX N2 **********************************************************
 
NATIONAL WORKSHOPS ON THE PROTECTION OF HUMAN SUBJECTS
National Institutes of Health
Food and Drug Administration
INDEX:  NATIONAL INSTITUTES OF HEALTH
        FOOD AND DRUG ADMINISTRATION
 
                       NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$INDEX R1 1/24/92 **************************************************
 
HISPANIC HEALTH AND AGING (AG-91-15)
National Institute on Aging
INDEX:  AGING
 
$$INDEX R2 1/24/92 **************************************************
 
HAZARDOUS MATERIALS AND WASTE WORKER HEALTH AND SAFETY TRAINING (ES-
92-01)
National Institute of Environmental Health Sciences
INDEX:  ENVIRONMENTAL HEALTH SCIENCES
 
$$INDEX R3 4/1/92 ***************************************************
 
NATIONAL COOPERATIVE PROGRAM ON MARKERS OF UTERINE RECEPTIVITY FOR
NONHUMAN BLASTOCYST IMPLANTATION (HD-92-02)
National Institute of Child Health and Human Development
INDEX:  CHILD HEALTH, HUMAN DEVELOPMENT
 
$$INDEX R4 1/22/92 **************************************************
 
COMMUNITY-BASED CARE FOR CHRONICALLY ILL OLDER PERSONS (NR-92-01)
National Center for Nursing Research
INDEX:  NURSING
 
$$INDEX R5 1/16/92 **************************************************
 
NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR THE TREATMENT OF HUMAN
IMMUNODEFICIENCY VIRUS INFECTION (AI-91-13)
National Institute of Allergy and Infectious Diseases
INDEX:  ALLERGY, INFECTIOUS DISEASES
 
$$INDEX R6 1/23/92 **************************************************
 
BASIC AND CLINICAL STUDIES ON THE MORBIDITY AND MORTALITY OF THE
END-STAGE RENAL DISEASE PATIENT (DK-92-07)
National Institute of Diabetes and Digestive and Kidney Diseases
INDEX:  DIABETES, DIGESTIVE, KIDNEY DISEASES
 
$$INDEX R7 1/22/92 **************************************************
 
GENETICS AND KIDNEY MATURATION, WITH AN EMPHASIS ON POLYCYSTIC KIDNEY
DISEASE (DK-92-08)
National Institute of Diabetes and Digestive and Kidney Diseases
INDEX:  DIABETES, DIGESTIVE, KIDNEY DISEASES
 
                     ONGOING PROGRAM ANNOUNCEMENTS
 
$$INDEX P1 **********************************************************
 
STUDIES ON THE MEDICAL AND HEALTH CONSEQUENCES OF DRUG ABUSE (PA-92-
16)
National Institute on Drug Abuse
INDEX:  DRUG ABUSE
 
                               ERRATA
 
$$INDEX E1 **********************************************************
 
RESEARCH SCIENTIST DEVELOPMENT AWARD (PA-91-101)
Alcohol, Drug Abuse, and Mental Health Administration
INDEX:  ALCOHOL, DRUG ABUSE, MENTAL HEALTH
 
$$INDEX E2 **********************************************************
 
RESEARCH SCIENTIST AWARD (PA-91-102)
Alcohol, Drug Abuse, and Mental Health Administration
INDEX:  ALCOHOL, DRUG ABUSE, MENTAL HEALTH
 
$$INDEX E3 **********************************************************
 
SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE IN BREAST CANCER (CA-91-
33)
National Cancer Institute
INDEX:  CANCER
 
$$INDEX E4 **********************************************************
 
SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE IN LUNG CANCER (CA-91-34)
National Cancer Institute
INDEX:  CANCER
 
$$INDEX E5 **********************************************************
 
SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE IN PROSTATE CANCER (CA-
91-35)
National Cancer Institute
INDEX:  CANCER
 
$$INDEX END *********************************************************
 
                               NOTICES
 
$$N1 BEGIN **********************************************************
 
CARDIOVASCULAR IMAGING WORKSHOP
 
P.T. 42; K.W. 0706030, 0705015, 0715040, 1002061, 0790000
 
National Heart, Lung, and Blood Institute
 
The National Heart, Lung, and Blood Institute (NHLBI) is sponsoring a
workshop entitled, "Cardiovascular Imaging Workshop," to be held on
March 2-4, 1992, at the National Institutes of Health, Lister Hill
Auditorium, Building 38A, Bethesda, MD.  The objective of this
workshop is the identification of opportunities for furthering
research in myocardial and vessel wall biology and physiology through
imaging and spectroscopic research.  Specific topics to be considered
are myocardial viability, perfusion and metabolism, and vessel wall
biology and plaque.
 
For registration information and a preliminary agenda, contact:
 
Rosalie A. Dunn, Ph.D.
Devices and Technology Branch
National Heart, Lung, and Blood Institute
National Institutes of Health
Federal Building, Room 312
Bethesda, MD  20892
Telephone:  (301) 496 1586
 
$$N1 END ************************************************************
 
$$N2 BEGIN **********************************************************
 
NATIONAL WORKSHOPS ON THE PROTECTION OF HUMAN SUBJECTS
 
P.T. 42; K.W. 0783005
 
National Institutes of Health
Food and Drug Administration
 
The National Institutes of Health (NIH) and the Food and Drug
Administration (FDA) are sponsoring a series of workshops on the
responsibilities of researchers, Institutional Review Boards (IRBs),
and institutional officials for the protection of human subjects in
research.  The workshops are open to everyone with an interest in
research involving human subjects.  The meetings should be of special
interest to those persons currently serving or about to begin serving
as a member of an IRB.  Issues discussed at these workshops are
relevant to all other Public Health Service agencies.  The current
schedule includes the following:
 
WEST COAST WORKSHOP
 
DATES:  January 23 and 24, 1992 (REVISED DATES)
 
WORKSHOP SITE:  Los Angeles, CA
 
SPONSORS:
University of Southern California
Los Angeles, CA  90089-4014
 
California State University - Los Angeles
5151 State University Drive
Los Angeles, CA  90032-8202
 
REGISTRATION CONTACT:
Ms. Lily Patterson
Assistant to the Director
Research and Sponsored Programs
California State University - Los Angeles
5151 State University Drive
Los Angeles, CA  90032-8202
Telephone:  (213) 343-3820
 
TOPIC:  Whose Research is it Anyway?  A Workshop on the Protection of
Human Subjects in Research
 
SOUTH MIDWESTERN WORKSHOP
 
DATES:  February 20 and 21, 1992
 
WORKSHOP SITE:  San Antonio, TX
 
SPONSORS:
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive
San Antonio, TX  78284-7972
 
St. Mary's University
One Camino Santa Maria
San Antonio, TX  78228-8572
 
REGISTRATION CONTACT:
Ms. Angie Khan
Institutional Coordinator of Research Review
University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive (Room 402L)
San Antonio, TX  78284-7972
Telephone:  (512) 567-2351
 
TOPIC:  Identifying and Assessing Risks in Human Subject Research
 
SOUTHWEST WORKSHOP
 
DATES:  March 24, 25, and 26, 1992
 
WORKSHOP SITE:
Sheraton Old Town Hotel
800 Rio Grande Blvd., N.W.
Albuquerque, NM  87104
 
SPONSORS:
University of New Mexico
Albuquerque, NM  87131-5126
 
Navajo Community College
Shiprock, NM  87420
 
REGISTRATION CONTACT:
University of New Mexico
Office of Continuing Medical Education
Health Sciences and Services Building (Room 140)
Box 713
Albuquerque, NM  87131-5126
Telephone:  (505) 277-3942
 
TOPIC:  Ethics, Justice, and Tribal Participation in Research with
American Indians
 
NOTE:  In conjunction with this Workshop, a session entitled, "Basic
Training for IRB Members," will be held from 1:00 p.m. on March 24
until noon on March 25.  During this session the Workshop
participants will be divided into four IRBs that will review four
different research protocols involving American Indians.  The full
conference will convene at 1:00 p.m. on March 25 and continue until
6:00 p.m. on March 26.
 
NORTHEASTERN WORKSHOP
 
DATES:  April 27 and 28, 1992
 
WORKSHOP SITE:  Philadelphia, PA
 
SPONSORS:
University of Pennsylvania
133 South 36th Street, Suite 300
Philadelphia, PA  19104-3246
 
Lincoln University
Lincoln University, PA  19352
 
REGISTRATION CONTACT:
Ms. Lynn Bevan
Assistant Director
Office of Research Administration
University of Pennsylvania
133 South 36th Street, Suite 300
Philadelphia, PA  19104-3246
Telephone:  (215) 898-2614
 
TOPIC:  The Shifting Ground:  Current Issues for the Protection of
Human Subjects in Biomedical and Behavioral Research
 
For further information regarding these workshops and future NIH/FDA
National Protection of Human Subjects Workshops, please contact:
 
Ms. Darlene Marie Ross
Executive Assistant for Education
Division of Human Subject Protections
Office for Protection from Research Risks
National Institutes of Health
9000 Rockville Pike
Building 31, Room 5B59
Bethesda, MD  20892
Telephone:  (301) 496-8101
 
$$N2 END ************************************************************
 
                  NOTICES OF AVAILABILITY (RFPs AND RFAs)
 
$$R1 BEGIN AG-91-15 FULL-TEXT ***************************************
 
HISPANIC HEALTH AND AGING
 
RFA AVAILABLE:  AG-91-15
 
P.T. 34, FD; K.W. 0710010, 0730000, 0408006, 0404000, 0417000,
1002019
 
National Institute on Aging
 
Letter of Intent Receipt Date:  December 1, 1991
Application Receipt Date:  January 24, 1992
 
PURPOSE
 
The National Institute on Aging (NIA) announces the availability of a
Request for Applications (RFA) for research on Hispanic health and
aging.  Investigations on the influence of genetic, social,
environmental, behavioral, and economic factors on morbidity and
mortality, as well as applications proposing research on the
utilization of health services among the Hispanic elderly are
requested.  In addition to the development of new data, secondary
analyses of existing data are acceptable.
 
There are currently one million elderly Hispanics living in the
continental United States, and this number is expected to grow to 5.6
million in less than 50 years -- a growth rate that is calculated to
be four times the rate of the overall elderly population.  Despite
the growth in the number of older Hispanics, information about their
health status, rehabilitation needs, and use of medical services is
scarce.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  Potential
applicants may obtain a copy of "Healthy People 2000" (Full Report:
Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report:
Stock No. 017-001-00473-1) through the Superintendent of Documents,
Government Printing Office, Washington, DC  20402-9325 (telephone
202- 783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Applications may be submitted by domestic for-profit and non-profit
organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State or local governments, and
eligible agencies of the Federal Government. Applications from
minority investigators and women are encouraged.
 
MECHANISM OF SUPPORT
 
Support of this program will be through the Public Health Service
grant-in-aid individual research grant (R01).  Awards will be
administered under PHS grants policy, as stated in the Public Health
Service Grants Policy Statement, DHHS Publication No. (OASH)
82-50,000, revised October 1, 1990.
 
The RFA is a one-time solicitation.  The award of grants pursuant to
the RFA is contingent on the availability of funds for this purpose.
Generally, future unsolicited competing renewal applications will
compete with all investigator-initiated applications and be reviewed
by the Division of Research Grants.  However, if the NIA determines
that there is a sufficient continuing program need, the RFA will be
reissued. The total project period for applications submitted in
response to the present RFA may not exceed five years.  The earliest
feasible start date for the initial awards will be July 1, 1992.
 
FUNDS AVAILABLE
 
Up to two million dollars in total (direct and indirect) first-year
costs, and additional direct costs for up to five years, will be
committed to fund up to six applications from those submitted in
response to this RFA.  This funding level is dependent on the receipt
of a sufficient number of applications of high scientific merit.
 
RESEARCH OBJECTIVES
 
This RFA solicits research on the following issues:
 
o  Epidemiological studies with a longitudinal focus on the causes
and course of selected health problems in elderly Hispanics.
 
o  Descriptive studies that characterize the association of chronic
diseases with disability among the Hispanic elderly.
 
o  Comparative studies testing the hypothesis that the Hispanic
elderly have more (or less) frailty and disability relative to
non-Hispanic subgroups.
 
o  Examination of the role of genetics among elderly Hispanics by
studying the relationship of American Indian ancestry to
susceptibility to specific diseases.
 
o  Studies of the interface between formal health and human services
and informal social supports among elderly Hispanics.
 
SPECIAL REQUIREMENTS
 
The Principal Investigators of funded projects, under the terms of
the awards, will meet in Bethesda with NIA staff yearly to review the
progress of their studies.  Funds for such travel must be requested
in the application.
 
STUDY POPULATIONS/SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN IN
CLINICAL RESEARCH STUDIES
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women in study
populations.  The nature of this solicitation satisfies the
requirement that minorities be included.  If women are not included
in the study populations for clinical studies, a specific
justification for this exclusion must be provided.  Applications
without such documentation will not be accepted for review.
 
REVIEW CONSIDERATIONS
 
Applications will be received by the NIH Division of Research Grants.
Responsive applications will be assigned to a special review group
organized by the NIA. Following this review, applications will be
considered by the National Advisory Council on Aging.
 
APPLICATION PROCEDURES
 
The deadline for receipt of applications is January 24, 1991.  The
grant applications may be obtained from the Division of Research
Grants, telephone (301) 496-7441.  A copy of the RFA contains
important information for applicants and may be obtained from Manuel
R. Miranda, Ph.D. (address below).
 
LETTER OF INTENT
 
A letter of intent to submit an application, while not required, is
requested.  the letter consists of a brief descriptive title, the
name of the Principal Investigator and other key investigators, and
the names and addresses of any other participating institutions.  The
letter of intent is requested in order to provide an indication of
the number and scope of applications to be reviewed.  The letter of
intent does not commit the sender to submit an application, nor is it
a requirement for submission of an application and does not enter
into the review of an application subsequently submitted.  This
letter is to be addressed to Dr. Manuel Miranda at the address listed
below.
 
INQUIRIES
 
Written and telephone inquiries concerning the RFA are encouraged.
The opportunity to clarify any issues or questions from potential
applicants is welcome.  Direct inquiries regarding programmatic
issues to:
 
Manuel R. Miranda, Ph.D.
National Institute on Aging
Interdisc. Research/Geriatrics Program
Building 31, Room 3B63
Bethesda, MD  20892
Telephone:  (301) 402-1115
 
Direct inquiries regarding fiscal matters to:
 
Mr. Joe Ellis
Grants Management Officer
National Institute on Aging
Building 31, Room 5C07
9000 Rockville Pike
Bethesda, MD  20892
Telephone:  (301) 496-1572
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance, No. 93.866, Biology of Aging Program.  Awards will be
made under the authority of the Public Health Service Act, Section
301 (42 USC 241) and administered under PHS Grants Policies and
Federal Regulations 42 CFR Part 52 and 45 CFR Part 74.  This program
is not subject to the intergovernmental review requirements of
Executive Order 12372 or review by a Health Systems Agency.
 
$$R1 END ************************************************************
 
$$R2 BEGIN ES-92-01 FULL-TEXT ***************************************
 
HAZARDOUS MATERIALS AND WASTE WORKER HEALTH AND SAFETY TRAINING
 
RFA AVAILABLE:  ES-92-01
 
P.T. 34; K.W. 0502017, 1007009, 0725020
 
National Institute of Environmental Health Sciences
 
Letter of Intent Receipt Date:  December 20, 1991
Application Receipt Date:  January 24, 1992
 
PURPOSE
 
The National Institute of Environmental Health Sciences (NIEHS)
announces the availability of a Request for Applications (RFA) for
cooperative agreements for training and education of workers engaged
in activities related to hazardous materials and waste generation,
removal, containment, transportation, and emergency response.
 
The major objective of this solicitation is to prevent work-related
harm by assisting in the training of workers in the best protection
of themselves and their communities from exposure to hazardous
materials encountered during hazardous waste operations and emergency
response.  A variety of sites, such as those involved with chemical
waste clean-up and remedial action and transportation-related
chemical emergency response, may pose severe health and safety
concerns.  These are often characterized by the multiplicity of
substances present, the presence of unknown substances, and the
general uncontrolled condition of the site.  A major goal of this
program is to assist organizations with the development of
institutional competency to provide appropriate training and
education to workers in the field of hazardous materials and waste.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a priority-setting process for Federal public health activities.
This Request for Applications (RFA), Hazardous Materials and Waste
Worker Health and Safety Training, is related to the priority areas
of occupational health and environmental health in the health
protection initiative. Potential applicants may obtain a copy of
"Healthy People 2000" (Full Report: Stock No. 017-001-00474-0)  or
"Healthy People 2000" (Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202-783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Applicants must be non-profit organizations that demonstrate
expertise and experience in implementing and operating training and
education programs for workers.  Such organizations must demonstrate
the ability to reach and involve in training programs the target
populations of workers.  Any non-profit organization providing worker
health and safety education and training may apply.
 
MECHANISM OF SUPPORT
 
Awards will be made as cooperative agreements (U01).  No commitment
of funds will be made beyond Fiscal Year 1994.  During FY 1992, the
NIEHS plans to fund between 15 and 20 cooperative agreements in
response to this RFA.  Awards will be made for up to three years with
annual renewal based on availability of funds, staff review of
progress toward achieving training objectives, and submission to the
NIEHS of copies of all training and educational materials used under
the award.  The anticipated starting date for the initial annual
period will be September 1, 1992.
 
The cooperative agreement is an assistance instrument similar to a
grant.  It differs in that in addition to the standard stewardship
role, the NIEHS program administrator is expected to have a
continuing substantive role in one or more technical aspects of the
program.  The type and degree of this substantial programmatic
involvement is specified in the terms and conditions of the
cooperative agreement.  The awardee will have lead responsibilities
in all aspects of the program, including any technical modifications
to the curriculum, conduct of the training, and quality control.
 
Applicants are expected to furnish their own estimates of the time
required to achieve specific training and education objectives of the
proposed training program and conduct appropriate program
evaluations.  Any substantial modifications in the program scope and
objectives must be mutually agreed upon by the awardee institution
and the NIEHS.  Because of the varied target audiences for the
proposed training and education programs, it is anticipated that a
variety of approaches will be responsive to this announcement and
that there will be a range of costs among individual awards.
 
TRAINING OBJECTIVES
 
Training programs shall satisfy minimum requirements for hazardous
waste workers and emergency responders as specified in Federal
Occupational Safety and Health Administration and other regulations
that have been or may be promulgated.  Training programs shall also
meet the minimum requirements specified in the Minimum Criteria for
Worker Health and Safety Training for Hazardous Waste Operations and
Emergency Response, published April 1990, as a result of an
NIEHS-sponsored technical workshop on training quality.  Previous
successful experience in conducting worker training programs for
these purposes will be an important review criterion.
 
Awards will be made for direct student and worker-trainer training,
technical support of training, and training program evaluation.  It
is believed that adequate curricula and training materials exist for
worker training that can be adapted with minimal effort.  Means of
multiplying training are also encouraged to meet the need; thus
programs such as effective train-the-trainer programs are encouraged.
Programs targeted to multi-state and nationwide coverage to reach
wider worker populations will be given preference in review and
funding. Applications will not be considered that cover
municipalities or other jurisdictions covering less than two states.
Programs are encouraged to develop plans to become self sufficient.
Applications must include plans for reaching underserved workers in
the proposed target populations, especially those disadvantaged in
education, culture, language, or literacy.
 
REVIEW PROCEDURES
 
Review of applications will not include a site visit for additional
information.  Therefore, it is essential that the application be as
complete as possible.  Applications will be reviewed on a competitive
basis for technical merit by an ad hoc peer review committee convened
by the NIEHS.  This committee will be primarily composed of
non-Government members with expertise in occupational health and
safety training related to hazardous materials, waste operations, and
emergency response.  The second level of review will be conducted by
the National Advisory Environmental Health Sciences Council.
 
APPLICATION PROCEDURES
 
Applications for Hazardous Materials and Waste Worker Health and
Safety Training Grants must be submitted on the grant application
form PHS 398 (rev. 10/88, reprinted 9/89).  This form is usually
available in the sponsored programs office at academic institutions.
However, since this form is used primarily for traditional NIH
research and training assistance, several sections have to be
modified and expanded to provide additional information needed for
worker training assistance applications.  Applicants may request a
copy of form PHS 398 from the Office of Grants Inquires, Division of
Research Grants, NIH, Room 449, 5333 Westbard Avenue, Bethesda, MD
20892-4500, telephone 301/496-7441.  Special instructions for worker
training applications are available from the Program Administrator,
Worker Training Grants Program, NIEHS, at the address listed below.
 
INQUIRIES
 
The NIEHS welcomes the opportunity to clarify any issues or questions
from potential applicants concerning this RFA.  Technical inquiries
regarding the objectives and scope of this RFA  and requests for a
copy of the RFA may be directed to:
 
Denny Dobbin
Program Administrator
Worker Training Grants Program
National Institute of Environmental Health Sciences
P.O. Box 12233
Research Triangle Park, NC  27709-2233
Telephone:  (919) 541-0752
 
Financial management inquiries may be directed to:
 
Carol Matheny
Grants Management Specialist
Grants Management Branch
National Institute of Environmental Health Sciences
P.O. Box 12233
Research Triangle Park, NC  27709-2233
Telephone:  (919) 541-2930
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance, No. 93.142, Superfund Worker Training Grants.  Awards
will be made under the authority of the Public Health Service Act,
Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241)
and Section 126(g) of the Superfund Amendments and Reauthorization
Act of 1986 and administered under PHS grants policies and Federal
Regulations 42 CFR Part 52 and 45 CFR Part 74.  This program is not
subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.  The program is
administered according to 42 CFR 45 -- Part 74 and Part 92, DHHS
Administration of Grants; 42 CFR Part 65, Special Regulations for
National Institute of Environmental Health Sciences Hazardous Waste
Worker Training, the PHS Grants Administration Manual, and PHS Grants
Policy Statement.
 
$$R2 END ************************************************************
 
$$R3 BEGIN HD-92-02 FULL-TEXT ***************************************
 
NATIONAL COOPERATIVE PROGRAM ON MARKERS OF UTERINE RECEPTIVITY FOR
NONHUMAN BLASTOCYST IMPLANTATION
 
RFA AVAILABLE:  HD-92-02
 
P.T. 34; K.W. 0760003, 0413002, 0760025, 1002004, 1002008
 
National Institute of Child Health and Human Development
 
Application Receipt Date:  April 1, 1992
 
PURPOSE
 
This is a notice of availability of a Request for Applications (RFA)
from established investigators in the area of blastocyst implantation
to participate in a National Cooperative Program to identify and
characterize markers indicative of the state of the uterus receptive
for blastocyst implantation.  Investigators will cooperate in an
interdisciplinary and complementary manner to achieve the goals of
identification and characterization of the uterine receptivity
markers.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of Healthy People 2000, a
PHS-led national activity for setting priority areas.  This RFA,
National Cooperative Program on Markers of Uterine Receptivity for
Nonhuman Blastocyst Implantation, is related to the priority area of
maternal and infant health.  Potential applicants may obtain a copy
of Healthy People 2000 (Full Report:  Stock No. 017-001-00474-0, or
Summary Report:  Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington,
DC  20402-9325 (Telephone 202-783-3238).
 
BACKGROUND INFORMATION
 
The National Institute of Child Health and Human Development (NICHD)
invites applications from investigators willing to participate, with
the assistance of the NICHD, in a multi-site Cooperative Research
Program designed to establish assayable markers for uterine
receptivity for blastocyst implantation and characterize the
involvement of these markers in the process of nonhuman blastocyst
implantation.
 
A Research Coordinator from the NICHD staff will collaborate with the
Principal Investigators of the awards in the planning, evaluation,
and publication of the research, and serve as a coordinator,
facilitator and partner in the conduct of the research program.  It
is expected that protocols will change as new information is gathered
and shared.
 
There are three program phases:  Phase I is to determine the
experimental approaches, protocol(s), and other research conditions;
Phase II is to implement and conduct the research; and Phase III is
to analyze and disseminate the results obtained.
 
ELIGIBILITY
 
Any domestic institution, both public and private, is eligible to
apply.
 
MECHANISM OF SUPPORT
 
The funding mechanism for fiscal assistance in this high priority
area of research will be cooperative agreements between participating
sites and the NICHD.  It is expected that up to six applications will
be funded, contingent upon the receipt of a sufficient number of
meritorious applications within a total direct cost program budget of
$900,000 (average direct cost of $150,000 per award) for the first
year.  The major difference between a cooperative agreement and a
research grant is that there will be substantial programmatic
involvement of the NICHD Research Coordinator above and beyond
conventional program and grant management procedures.
 
REVIEW PROCEDURES
 
Applications will receive a preliminary review for responsiveness to
this RFA and may receive a triage review for relative competitiveness
by peer review. Applications judged to be competitive for awards will
be reviewed for scientific and technical merit by a review committee
convened specifically for this purpose by the Division of Scientific
Review, NICHD.  A second-level review will be done by the National
Advisory Child Health and Human Development Council.
 
METHOD OF APPLYING
 
Applications must be submitted on form PHS 398 (rev. 10/88, reprinted
9/89), that is available in most institutional business offices and
from the Division of Research Grants, NIH (telephone 301/496-7441).
 
INQUIRIES
 
Potential applicants may request further information and copies of
the RFA that outlines the requirements for participation in this
program from:
 
Koji Yoshinaga, Ph.D.
Reproductive Sciences Branch
Center for Population Research
National Institute of Child Health and Human Development
Executive Plaza North, Room 603
Bethesda, MD  20892
Telephone:  (301) 496-6515
 
Administrative Policy:
 
Ms. Melinda Nelson
Office of Grants and Contracts
National Institute of Child Health and Human Development
National Institutes of Health
Executive Plaza North, Room 505
Bethesda, MD  20892
Telephone:  (301) 496-5481
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance No. 93.864, Population Research. Awards will be made under
the authority of the Public Health Service Act 301 (42 USC 241) and
441 (USC 289d) and administered under PHS Grants Policies and Federal
Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not
subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review.
 
$$R3 END ************************************************************
 
$$R4 BEGIN NR-92-01 FULL-TEXT ***************************************
 
COMMUNITY-BASED CARE FOR CHRONICALLY ILL OLDER PERSONS
 
RFA AVAILABLE:  NR-92-01
 
P.T. 34; K.W. 0710010, 0730000, 0745035, 0785130
 
National Center for Nursing Research
 
Letter of Intent Receipt Date:  January 22, 1992
Application Receipt Date:  March 10, 1992
 
PURPOSE
 
The National Center for Nursing Research (NCNR) announces the
availability of a Request for Applications (RFA) dealing with the
efficacy and effectiveness of clinical interventions for the long
term care of chronically ill older persons who reside in the
community.  The overall purpose of the interventions must be to
manage commonly experienced symptoms, prevent the onset of further
disabilities, and facilitate the transition among health care
settings and home.  These outcomes would be expected to encourage
independence, enhance health-related quality of life, and enable
chronically ill older persons to remain at home.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Community-Based Care for Chronically Ill Older Persons, is related to
the priority areas of older persons as a targeted group and to
chronically disabling conditions.  Potential applicants may obtain a
copy of the "Healthy People 2000" (Full Report:  Stock No. 017-
001-00474-0 or Summary Report:  Stock No. 017-001-00473-1) through
the Superintendent of Documents, Government Printing Office,
Washington, DC  20402-9325 (telephone 202-783-3238).
 
ELIGIBILITY REQUIREMENTS
 
Applications may be submitted by domestic and foreign, for-profit and
non-profit, public and private, organizations such as universities,
colleges, hospitals, laboratories, units of State or local
governments, and eligible agencies of the Federal Government.
Applications from minority individuals and women are encouraged.
 
MECHANISM OF SUPPORT
 
This RFA is a one-time solicitation for research grant (R01)
applications.  The total project period for applications submitted in
response to the present RFA may not exceed four years.  The
anticipated award date will be September 30, 1992.
 
FUNDS AVAILABLE
 
Approximately $1,000,000 in total costs for the first year will be
committed to specifically fund applications submitted in response to
this RFA.  It is anticipated that five applications will be funded.
This level of support is dependent on the receipt of a sufficient
number of applications of high scientific merit.  Although this
program is provided for in the financial plans of the NCNR, the award
of grants pursuant to this RFA is also contingent upon the
availability of funds for this purpose.
 
RESEARCH OBJECTIVES
 
This initiative builds directly on the work of a panel of scientific
experts on long term care convened as part of the development of the
National Nursing Research Agenda.  The work of this panel is
currently nearing completion with the anticipated publication of its
report in 1992.  The goal of this RFA is to stimulate the development
of innovative clinical interventions for community-based chronically
ill older persons in order to manage commonly experienced symptoms,
prevent the onset of further disabilities, and facilitate the
transition between health care settings and home.  These outcomes
would be expected to encourage independence, enhance health-related
quality of life, and enable the chronically ill older person to
remain at home.  The theoretical basis for the planned study must be
clearly explicated and linked to the clinical interventions to be
developed and tested.  It is important that the interventions be
carefully and clearly defined in terms of their purpose, composition,
means of implementation and anticipated effect. Particular attention
must be paid to ensuring that the anticipated effects have clearly
defined outcome measures.
 
The proportion of the population that is 65 years and greater is
increasing rapidly.  Most of these older persons live in the
community and do not need institutional care.  However, the longer a
person survives, the more likely he or she is to become chronically
ill or disabled and the more likely nursing home care will be needed
at some point in the continuum of care.  Admission to a nursing home
has been described as a terminal event for many older persons, rather
than as a useful health care setting for those who need subacute
institutional care for a period of time. Studies that have examined
the continuity of care for older persons generally have focused on
the movement between acute care and nursing homes.  The investigation
of transitions from the community to nursing home or hospital care
and back have not received much emphasis. Clinical interventions are
needed to address the transitions across health care settings made by
chronically ill, home based older persons.
 
The functioning of the family and/or informal caregivers can have a
significant effect on the health outcomes of the chronically ill
older person.  There have been indications that certain factors, such
as living alone and urinary incontinence, influence the decision to
remove older persons from their homes and to admit them to a nursing
home.  It is possible that well- functioning family systems and
community social support networks are instrumental in averting or
delaying these admissions and in assisting in the return of these
individuals to the community.
 
In addition to these community-based care issues, the clinical
interventions may address the human responses exhibited by older
people who have chronic illness.  The older adult with chronic
illness is at risk for decline in health and functional status due to
a number of factors, including those related to adherence to
treatment regime, the onset of physical symptoms that impede daily
activities, and behavioral responses to the changes occurring with
increasing age and length of illness.  Because chronic health
problems can lead to increased disabilities and frailty, early,
efficacious and effective intervention strategies should lead to
improved outcomes.  In general, there is a paucity of research
dealing with symptom management of the chronically ill older person,
but what research exists has usually been done in either acute care
or nursing home settings.  There is clearly a need to identify
strategies to deal with symptoms experienced by persons who are
community based.  Symptoms and conditions such as cognitive or
behavioral problems, confusion, decreased mobility, skin integrity
problems such as pressure ulcers, incontinence, nutrition and
hydration problems, and altered sleep and rest patterns frequently
limit the ability to function normally, impair autonomy, and decrease
the health-related quality of life.  Interventions dealing with these
and other symptoms related to chronic illnesses need to address both
behavioral and biophysiological/physical components.  Applications
from interdisciplinary research teams are encouraged.
 
Applications are invited for support of clinical intervention studies
concerning community-based care of chronically ill older persons.
Studies may include, but are not limited to:
 
o  design and test interventions to effectively manage physical and
behavioral symptoms of frequently occurring chronic illnesses in
older persons;
 
o  design and test interventions that prevent complications and
minimize disability in older persons with chronic illness;
 
o  design and test clinical interventions to facilitate the
coordination of care and transition across health care settings for
older adults;
 
o  design and test interventions to support family members or family
systems involved in the care of older persons with chronic illness.
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN
CLINICAL RESEARCH STUDY POPULATIONS
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.
 
APPLICATION AND REVIEW PROCEDURES
 
The RFA contains important information for applicants and may be
obtained either Patricia Moritz, Ph.D., or Mary D. Lucas, Ph.D.
(address below).  The application receipt date is March 10, 1992.
The research grant application form PHS 398 (rev. 10/88, reprinted
9/89) must be used in applying for these grants.  These forms are
available from the Division of Research Grants, telephone
301-496-7441.  Applications must be submitted to the NIH Division of
Research Grants and will be assigned to a special review group
organized by NCNR.  Following this review, applications will be
considered by the NCNR National Advisory Council.
 
LETTER OF INTENT
 
A letter of intent while not required, is requested by January 22,
1992.  The letter of intent is to include a descriptive title, the
name, address, and telephone number of the Principal Investigator,
the identities of other key personnel, and any other participating
institutions.  Letters are to be sent to:
 
Ethel Jackson, DDS
Chief and Scientific Review Administrator
National Center for Nursing Research
Building 31, Room 5B19
9000 Rockville Pike
Bethesda, MD  20892
 
INQUIRIES
 
Written and telephone inquiries concerning this RFA are encouraged.
The opportunity to clarify any issues or questions from potential
applicants is welcome.
 
Direct inquiries regarding programmatic issues to:
 
Patricia Moritz, Ph.D., R.N.
Chief, Nursing Systems Branch
 
or
 
Mary D. Lucas, Ph.D., R.N.
Chief, Acute and Chronic Illness Branch
National Center for Nursing Research
Building 31, Room 5B03
Bethesda, MD  20892
Telephone: (301) 496-0523
 
Direct inquiries regarding fiscal matters to:
 
Sally Nichols
Grants Management Officer
National Center for Nursing Research
Building 31, Room 5B06
Bethesda, MD  20892
Telephone:  (301) 496-0237
 
OTHER INTERESTS IN THIS RESEARCH AREA
 
The National Institute on Aging and the Agency for Health Care Policy
and Research are also interested in research dealing with long-term
care issues.  The RFA contains additional information and program
contacts.
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance No. 93.336, Nursing Research, and No. 93.866.  Awards are
made under authorization of the Public Health Service Act, Title IV,
Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC
241 and 285) and administered under PHS grants policies and Federal
Regulations 42 CFR 52 and 45 CFR Part 74.  This program is not
subject to the intergovernmental review requirements of Executive
Order 12372 or Health Systems Agency review, April 6, 1988.
 
$$R4 END ************************************************************
 
$$R5 BEGIN AI-91-13 FULL-TEXT ***************************************
 
NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR THE TREATMENT OF HUMAN
IMMUNODEFICIENCY VIRUS INFECTION
 
RFA AVAILABLE:  AI-91-13
 
P.T. 34; K.W. 0715008, 0740020, 0755025
 
National Institute of Allergy and Infectious Diseases
 
Letter of Intent Receipt Date:  November 28, 1991
Application Receipt Date:  January 16, 1992
 
The National Institute of Allergy and Infectious Diseases (NIAID)
announces availability of a Request for Applications (RFA) for
funding of the National Cooperative Drug Discovery Groups for the
Treatment of Human Immunodeficiency Virus Infection (NCDDG-HIV).  It
is the purpose of this RFA to invite applications aimed at the
discovery of more effective, selective, and diverse new agents that
can be used for the treatment of HIV, the etiological agent
associated with Acquired Immunodeficiency Syndrome (AIDS).
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
National Cooperative Drug Discovery Groups for the Treatment of HIV
Infections (NCDDG-HIV), is related to the priority area of HIV
infection.  Potential applicants may obtain a copy of "Healthy People
2000" (Full Report:  Stock No. 017- 001-00474-0) or "Healthy People
2000" (Summary Report: Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington,
DC  20402-9325 (telephone 202-783-3238).
 
RESEARCH OBJECTIVES AND SCOPE
 
The prime objective of this RFA is to stimulate original and
innovative research of sound scientific rationale, requiring
comprehensive team effort, that is likely to result in the discovery
of agents effective against HIV.  In line with this objective, the
NCDDG-HIV program supports and implements projects for innovative and
under-exploited studies that are at the cutting edge of biomedical
research. Such studies may have a greater risk-to-benefit quotient
than is currently acceptable under the more traditional investigator
initiated (R01) mechanism but may also have a greater potential for
effective, long-term therapeutic returns.  In addition to the
scientific criteria, these efforts are to be implemented through a
collaborative, concerted effort by components of the Group.
Applications in which collaboration among components of the Group are
not required for the success of Group activities will not be funded
and are encouraged to submit an individual investigator-initiated
(R01) or equivalent grant application.
 
Applications that include research projects or a core components from
the private sector (e.g., pharmaceutical, chemical, or
biotechnological companies) are strongly encouraged.  Research
directed toward drug discovery in the following major areas will be
considered responsive to this RFA:
 
o  Discovery, elucidation, and application of modalities that inhibit
HIV gene expression via interference with HIV regulatory elements;
 
o Inhibition of critical steps in HIV replication via intracellular
delivery or expression (gene therapy) of antagonists using viral
vectors or other delivery strategies;
 
o Intervention with cellular biochemical pathways required for
induction from latency and/or for enhancement of HIV growth cycle;
 
o Innovative approaches to exploit the humoral and cellular arms of
the immune system in a targeted anti-HIV affront;
 
o Other sound and conceptually new strategies, currently not being
pursued, for the discovery of new entities or combinations with
potential for treatment of HIV infection, such as inhibitors of viral
penetration, ribozymes, and agents that disrupt virus structure.
 
Examples of proposed research in these major areas are: studies to
delineate structure-function of HIV encoded target proteins; evaluate
drug metabolism; devise and evaluate innovative drug delivery
strategies; appraise the emergence of resistance to drugs targeted to
specific HIV enzymatic, structural, or regulatory function; identify
early events in viral replication suitable for drug targeting; and
decipher biochemical pathways and host interactions critical to virus
replication and/or drug action.
 
Projects or cores with proposed animal model development or efficacy
testing in animal models must be integrated into and required to
attain the Group's objectives.  Animal model component(s) may be
requested by the NIAID to evaluate in vivo compounds other than
compounds generated by the Group. Funds awarded for the evaluation of
new agents in animal models will be withheld until compounds
generated by the Group or provided by the NIAID are available for
animal efficacy studies.  Projects utilizing non-random cell-based
assays for screening natural products, biologics and/or synthetic
compounds must not exceed 25 percent of the total level of effort of
the Group.
 
The following research areas currently under intense investigation or
that have already been integrated into other NIH initiatives are
specifically excluded from this RFA:  (i) synthesis or development of
analogues or prodrugs of known anti-HIV nucleosides and
non-nucleosides; (ii) reverse transcriptase screens; (iii) evaluation
of recombinant human cytokines; (iv) development of exogenous,
soluble CD4 or its conjugated congeners; (v) anti-protease screens
and peptide-based protease inhibitors; (vi) evaluation and synthesis
of myristoylation inhibitors; (vii) mechanism of action studies
unlinked to inhibitor identification; (viii) large-scale random
screening of compounds with potential activity against HIV in cell
culture-based systems (such a program is operated by the National
Cancer Institute); (ix) research on the opportunistic infections
associated with AIDS (a separate RFA for the National Cooperative
Drug Discovery Groups for the Treatment of Opportunistic Infections
Associated with AIDS has been re-issued (NIH GCG, Vol. , No., date),
for the third consecutive year).  Scientists whose research does not
lie within the areas defined as responsive to this RFA are encouraged
to apply for investigator-initiated research (R01) grants.
 
Each NCDDG-HIV will be assembled by the Principal Investigator to
form a multi-disciplinary consortium representing the various skills
needed to successfully design, implement, and evaluate - at the
preclinical level - therapeutic entities and strategies for the
treatment of AIDS.  Inasmuch as it is unlikely that all of the
outstanding talents required to exploit fundamental leads from
various scientific disciplines will be found in a single institution,
each Group is envisioned as being multi- institutional as well.
Thus, each NCDDG-HIV will consist of a number of research projects
representing the scientific disciplines required to attain the
Group's goals and objectives.  The various research projects,
including that of the Principal Investigator, may be mobilized from
academia, research institutions, and/or industry;  the incorporation
of a component from the private sector is strongly encouraged.  It is
expected that the rationale for design of potential treatments, the
synthesis of specific agents, and the preclinical models for
evaluation will originate within the Group and be based on leads from
the group and the fundamental research of others.  Specifically
excluded from the Group's activities are activities related to
clinical evaluation of the drug.
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN
CLINICAL RESEARCH STUDIES
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.
 
MECHANISMS OF SUPPORT
 
Awards will be made as Cooperative Agreements (U01).  The Cooperative
Agreement funding mechanism differs from the traditional research
grant in that the Government component (NIAID) awarding the
Cooperative Agreement anticipates substantial programmatic
involvement during performance. The nature of the NIAID staff
participation is described in the RFA.  However, the applying Group
must define its objectives in accord with its own interests and
perceptions of approaches to combat HIV infection.
 
REVIEW PROCEDURES
 
Applications will be reviewed by the appropriate subcommittee of the
NIAID AIDS Research Review Committee. NIAID has set aside $2.2
million total cost for the initial year funding.  An NCDDG-HIV award
is subject to a current limit of $1,000,000 in total costs (direct
plus indirect costs) for the first year.  The amount spent will be
dependent on the continuing availability of funds for this purpose
and the quality and diversity of approved applications.
 
TERMS OF AWARD
 
The proposed applicant institution will be responsible for the Group
application.  Awards will be made to the applicant's institution on
behalf of the Group as a whole and not to individual research
projects within the Group.  The applicant institution will provide a
Central Operations Office for the Group.  The applicant institution
will be responsible for the performance of the entire Group and will
be accountable for the funds awarded.  The active participation of
the Government through the NIAID extramural staff is aimed at
enhancing and expediting a concerted effort by the Group by making
available biological materials for testing, appropriate existing data
bases, and appropriate ancillary testing and other resources
available under existing contracts.  The interaction of academic and
non-profit research institutions with commercial organizations and
Government is strongly encouraged and is expected to promote
innovative discoveries of anti-HIV treatment and will facilitate
their subsequent development to clinical trial.
 
METHOD OF APPLYING
 
The deadline for receipt of applications is January 16, 1992.
Applications received after this date will be considered as not
responsive to this RFA and will be returned without review.
 
The regular research grant application forms PHS 398 (rev. 10/88 or
9/89) are available at most institutional business offices.  If not
available there, they may be obtained from:  Office of Grants
Inquiry, Division of Research Grants, Westwood Building, Room 449,
5333 Westbard Avenue, Bethesda, MD 20892, telephone:  301/496-7441.
 
LETTER OF INTENT
 
Prospective applicants are asked to submit by November 28, 1991, a
letter of intent that includes a descriptive title of the overall
proposed research, the name and institution of the Principal
Investigator, a title for each component research project and brief
descriptions of the proposed projects.  Names of prospective Project
Leaders and other key investigators and their institutions should be
included (maximum of two pages).  The letter of intent is requested
in order to provide an indication of the number and scope of
applications to be reviewed and in order to allow early preparations
for review as well as promote early interactions between applicants
and NIAID staff.  The letter of intent does not commit the sender to
submit an application, nor is it a requirement for submission of an
application.  The letter of intent is to be sent to:
 
Nava Sarver, Ph.D.
Chief, Targeted Drug Discovery Section
Developmental Therapeutics Branch Division of AIDS
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 246P
Bethesda, MD  20892
Telephone:  (301) 496-8197
 
INQUIRIES
 
This RFA is available from:
 
Ms. Besita Wyche
Targeted Drug Discovery Section
Developmental Therapeutics Branch Division of AIDS
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard
Bethesda, MD  20892
Telephone:  (301) 496-8197
 
Inquiries regarding matters pertaining to the review of this
application should be addressed to Dr. Hornbeak.
 
Hortencia Hornbeak, Ph.D.
Deputy Chief, Program and Project, DEA
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard
Bethesda, MD  20892
Telephone:  (301) 496-0123
 
Inquiries regarding fiscal matters may be addressed to Mr. Thompson.
 
Mr. Gary Thompson
Chief, Grants Management Branch
Review Branch, DEA
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard
Bethesda, MD  20892
Telephone:  (301) 496-7231
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance, 93.856 - Microbiology and Infectious Diseases Research
and 93.855 - Immunology, Allergic and Immunological Diseases
Research.  Grants are awarded under the authority of the Public
Health Service Act, Section 301 (42 USC 241) and administered under
the PHS grants policies and Federal Regulations, most specifically at
42 CFR Part 52 and 45 CFR Part 74.  This program is not subject to
the intergovernmental review requirements of the Executive Order
12372 or Health Systems Agency Review.
 
$$R5 END ************************************************************
 
$$R6 BEGIN DK-92-07 FULL-TEXT ***************************************
 
BASIC AND CLINICAL STUDIES ON THE MORBIDITY AND MORTALITY OF THE
END-STAGE RENAL DISEASE PATIENT
 
RFA AVAILABLE:  DK-92-07
 
P.T. 34; K.W. 0755015, 0785095, 0785165, 0745025, 0745065
 
National Institute of Diabetes and Digestive and Kidney Diseases
 
Letter of Intent Receipt Date:  December 11, 1991
Application Receipt Dates:  January 23, 1992
 
The Division of Kidney, Urologic and Hematologic Diseases (DKUHD) of
the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) announces the availability of a Request for Applications
(RFA) on the above subject.
 
BACKGROUND
 
Most organ systems are affected by the development of renal failure
and the uremic state.  The treatment regimen for these patients
consists of either a dialysis modality or a renal allograft.  The
annual mortality rate of the dialysis patient population in the
United States is approximately 20 percent, almost double that
reported by European countries and Japan.  This high mortality rate
underscores the need for research on the causes of morbidity and
mortality in the end-stage renal disease (ESRD) population.
 
HEALTHY PEOPLE 2000
 
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of HEALTHY PEOPLE 2000, a
PHS-led national activity for setting priority areas.  This RFA is
related to the priority area of "Diabetes and Chronic Disabling
Conditions."  Potential applicants may obtain a copy of "Healthy
People 2000" (Full Report:  Stock No. 017-001-00474-0) or "Healthy
People 2000" (Summary Report:  Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington,
DC 20402-9325 (telephone 202-783-3238).
 
RESEARCH GOALS AND SCOPE
 
It is the objective of this RFA to stimulate fundamental, clinical
and applied research activity towards:  (1) better understanding of
the causes of ESRD; (2) decreasing the rate at which chronic renal
failure progresses; (3) enhancing the quality and effectiveness of
dialysis and transplantation; and (4) reducing the complications
associated with these therapies.
 
The following are some suggested topics that might be addressed to
achieve the objectives of this solicitation:
 
o  Cardiovascular Influences:  The effects on cell and organ function
that result from the acute fluid and electrolyte shifts induced by
dialysis treatment; organ specificity of these changes in the volume
and composition of the body fluids, and laboratory indicators that
might have clinical utility in the management of dialysis patients.
 
o  Vascular Access:  Development of new access concepts, materials,
and designs; tissue reactions to new biomaterials.  Studies of the
roles of coagulation, fibrinolytic, complement, and other mediator
systems.
 
o  Hormonal and Metabolic Influences:  Studies to assess the
quantitative impact of various hormones, especially insulin, on
protein and amino acid metabolism in chronic renal failure.
 
o  Infection and Immunity Problems:  Studies directed at elucidating
the role of cytokines in the morbid and mortal events in the uremic
state.  Fundamental studies of immune dysfunction in uremia.
 
o  Nutritional Influences:  In vivo studies assessing whole body
protein turnover (synthesis and breakdown) and of regional aspects of
protein and amino acid metabolism. Studies to better define optimal
nutrition interventional approaches for patients on dialysis.
 
o  Epidemiologic Studies:  Studies addressing the role of nutritional
factors in the pathogenesis of infections, and the influence of
biomaterials on infection rates in the dialysis population.
 
ELIGIBILITY
 
Research grant applications may be submitted by domestic and foreign,
non-profit and profit-making organizations and institutions, State
and local governments and their agencies, and eligible agencies of
the Federal Government.  Applications from women and minorities are
encouraged.
 
MECHANISMS OF SUPPORT
 
Applications may be submitted for the traditional,
investigator-initiated research project grant (R01). Support will be
provided for up to five years (renewable for subsequent periods),
subject to the availability of funds and progress achieved.
 
REVIEW PROCEDURES AND CRITERIA
 
Upon receipt, applications will initially be reviewed by the Division
of Research Grants (DRG) for completeness. Incomplete applications
will be returned to the applicant without further consideration.
Applications will then be reviewed by program staff for their
responsiveness to the objectives of this RFA.  If an application is
considered unresponsive, the applicant will be contacted and given an
opportunity to withdraw the application or have it considered an
unsolicited grant application in the next review cycle.
 
METHOD OF APPLYING
 
Applications must be submitted using form PHS 398 (rev. 10/88).  This
form is available in the business or grants office of most academic
or research institutions and from the Office of Grants Inquiries,
Division of Research Grants, National Institutes of Health, 5333
Westbard Avenue, Room 449 Bethesda, MD  20892, telephone 301/496-
7441.
 
LETTER OF INTENT
 
Prospective applicants are encouraged to submit an optional letter of
intent, that includes the title of the proposed project and
identification of all participating institutions.  Such letters are
requested only for the purpose of obtaining an indication of the
number and scope of applications to be received.  A letter of intent
is not binding, is not a requirement of submission, and it will not
enter into the review of the application subsequently submitted.
This letter is to be received no later than December 11, 1991, and is
to be sent to:
 
Robert D. Hammond, Ph.D.
Chief, Review Branch, Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 406
Bethesda, MD  20816
 
SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN
CLINICAL RESEARCH STUDIES
 
For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations of clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.
 
FUNDS AVAILABLE
 
For FY 1992, $1.5 million in total costs per year will be committed
to fund applications submitted in response to this RFA.  It is
anticipated that eight to ten awards will be made.  In order to meet
NIDDK goals for managing the costs of biomedical research, applicants
must limit their requests to not more than $160,000 in direct costs
for the first year.  Awards are contingent upon the availability of
funds.  The earliest award date will be July 1, 1992.
 
INQUIRIES
 
It is essential that prospective applicants obtain the RFA prior to
developing an application.  The RFA can be obtained from:
 
M. James Scherbenske, Ph.D.
Program Director, Renal Physiology/Cell Biology
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 3A-04A
Bethesda, MD  20892
Telephone:  (301) 496-7458
 
For fiscal and administrative matters, contact:
 
Mrs. Helen Y.S. Ling
Grants Management Specialist
Grants Management Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 639
Bethesda, MD  20892
Telephone:  (301) 496-7467
 
AUTHORITY AND REGULATIONS
 
This program is described in the Catalog of Federal Domestic
Assistance No. 93.849.  Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as